Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
All patients were younger than 10 years of age. The patients received either high-dose treatments (0.5–1.0 mg subconjunctival depot, dexamethasone 4 mg/mL, or methylprednisolone acetate 40mg/mL,, and ...